Hikma narrows 2026 operating profit outlook to $740 million-$760 million
Bitget2026/11/05 07:15- Hikma Pharmaceuticals narrowed its 2026 operating profit forecast to $740 million-$760 million from $720 million-$770 million.
- Group revenue growth guidance remains at 2%-4%, with year-to-date performance in line with expectations.
- Branded revenue growth guidance increased to around 10% from 6%-8%, supported by strong demand.
- Branded core operating margin is forecast near 27%, up from around 25%, reflecting a strong product mix despite increased marketing spending.
- Injectables revenue is now expected to remain broadly flat rather than grow by low single digits; core operating margin guidance remains 27%-28%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stock futures fluctuate by $650 billions due to news related to Jensen Huang
Nikkei Average Index gains expand to 2.78%
Surprise! Japan intervened in the forex market three times this summer, selling a record 154 trillion yen in three days
Japan has confirmed that it intervened in the foreign exchange market three times this summer, buying yen to support the exchange rate, corroborating earlier market reports. This included the first joint intervention with the United States to support the yen in nearly thirty years.
UBS CEO warns: A Democratic sweep could slow down AI capacity building, valuation concerns are "very important"
UBS CEO Ermotti stated that the U.S. midterm elections may slow down AI capacity building and that the valuations are questionable; he also warned of persistent inflation and the risk of contagion in the European bond market.
Crypto prices
More
